|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||30.550 - 30.850|
|52 Week Range||26.300 - 32.420|
|Beta (3Y Monthly)||0.44|
|PE Ratio (TTM)||19.93|
|Forward Dividend & Yield||1.08 (3.63%)|
|1y Target Est||33.70|
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
SOUTH SAN FRANCISCO, Calif.-- -- Rituxan label updated to include information for follow up treatment in adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment Rituxan in combination with glucocorticoids is the only FDA-approved therapy for these rare, potentially life-threatening blood vessel disorders Genentech, ...
AbbVie (ABBV) has seen its marketing application for its drug Imbruvica combined with Roche (RO.SW)'s Gazyva, accepted by the U.S. Food and Drug Administration for a priority review as treatment for adult patients affected with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). If the U.S. agency approves the marketing application, the combined therapy of AbbVie's Imbruvica and Roche's Gazyva will be the first treatment given for lymphocytic leukaemia or small lymphocytic lymphoma.
Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.
AG (ROG.EB) said Wednesday that its nine-month group sales rose on year, buoyed by new drugs. The Basel, Switzerland-based company said its nine-month group sales rose to 42.08 billion Swiss francs ($42.55 billion) up from CHF39.43 billion the year before. In the pharmaceuticals division, sales rose to CHF32.70 billion, up from CHF30.63 billion the year before.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP ) Krystal Biotech ...
Roche's (ROG.S) third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries. Third-quarter sales rose 7 percent to 13.97 billion Swiss francs (£10.7 billion), the Swiss drugmaker said on Wednesday, compared with analysts' average forecast of 13.8 billion francs in a Reuters poll. The company is also getting increasing support from its expansion in China, where sales of Avastin, Rituxan and Herceptin are on the rise and where regulators in August gave quick approval to one of Roche's newest medicines, Alecensa, for a tough-to-treat lung cancer mutation.
Trading updates from a number of European companies, including Danone, Pearson and Roche made the headlines on a busy day of corporate news in the region.
Roche's third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries. Third-quarter sales rose 7 percent to 13.97 billion Swiss francs ($14.10 billion), the Swiss drugmaker said on Wednesday, compared with analysts' average forecast of 13.8 billion francs in a Reuters poll. The company is also getting increasing support from its expansion in China, where sales of Avastin, Rituxan and Herceptin are on the rise and where regulators in August gave quick approval to one of Roche's newest medicines, Alecensa, for a tough-to-treat lung cancer mutation.
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
- Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise - SQZ to receive up to $125 million in upfront and near-term milestone payments WATERTOWN, ...
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant ...
OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (EBC) who have residual disease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. The safety profile of Kadcyla in the KATHERINE study was consistent with previous clinical trials and no new safety signals were identified.
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Over the past 11 years, OTC Markets Group, operator of the over the counter equities markets, has organized this market into a tiered system based on the quality and timeliness of information a company has disclosed. The goal of organizing by tiers, according to Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, was to help investors better understand the array of companies that trade here and the corresponding risks.
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
The tussles in the biosimilars market are a growing focus for investors, with soaring valuations for some pioneers in the field, including Celltrion, and worries about the long-term sales threat to makers of the original drugs such as Roche and AbbVie (ABBV.N). The vote comes after FDA staff reviewers https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM622649.pdf said Celltrion's biosimilar, CT-P10, was highly similar to Rituxan.
Celltrion Inc's biosimilar of Roche Holding AG's blockbuster cancer drug, Rituxan, on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration. The tussles in the biosimilars market are a growing focus for investors, with soaring valuations for some pioneers in the field, including Celltrion, and worries about the long-term sales threat to makers of the original drugs such as Roche and AbbVie. The vote comes after FDA staff reviewers https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM622649.pdf said Celltrion's biosimilar, CT-P10, was highly similar to Rituxan.
Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.
AG in a deal that could be worth up to $760 million for Ionis. As part of the deal to develop a drug called IONIS-FB-L(Rx) for the treatment of a wide range of diseases, Ionis will get a $75 million upfront payment and will then be eligible to receive up to $684 million in development, regulatory and sales milestone payments and license fees. Ionis is responsible for conducting a Phase 2 study, slated to begin in early 2019, in patients suffering from age-related macular degeneration -- the leading cause of blindness in the U.S. and developed countries -- and exploring the drug in a rare severe renal indication.
OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 10-12 in Berlin, Germany. Five-year data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO show OCREVUS efficacy is maintained on key measures of disease activity and that people treated earlier with OCREVUS had superior disability progression outcomes compared with RMS patients who switched from interferon beta-1α or PPMS patients who switched from placebo. The new data presented at ECTRIMS demonstrate that OCREVUS’ efficacy continued over five years in relapsing and primary progressive MS, and notably, include the largest body of evidence for any medicine to significantly slow disability progression in primary progressive MS,” said Stephen Hauser, M.D., chair of the Scientific Steering Committee of the OPERA studies, professor of neurology at the University of California, San Francisco, and director of the UCSF Weill Institute for Neurosciences.
Ionis Pharmaceuticals generated second-quarter revenues of $118.0 million compared to $122.3 million in the second quarter of 2017, which reflected ~15.0% YoY (year-over-year) growth. In the first half, Ionis Pharmaceuticals reported revenues of $262.2 million, compared to $228.1 million in the first half of 2017.
Roche’s (RHHBY) Neurology segment generated net combined revenues of 1.4 billion Swiss francs in the first half of this year, reflecting 164.0% YoY (year-over-year) growth on a constant exchange basis. This segment consists of Ocrevus, Madopar, and other drugs. Ocrevus primarily pushed the revenue growth of Roche’s Neurology business.
– First positive Phase III study results for a cancer immunotherapy combination in breast cancer, with Tecentriq® plus nab-paclitaxel –
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.